Q-omics provides the consensus-scored SCGB1D5P profile across patient tissues and cancer cell-line models. SCGB1D5P expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SCGB1D5P is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, SCGB1D5P RNA expression shows 8,704 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight LIHC, KIRC, and ESCA as cancer lineages where SCGB1D5P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCGB1D5P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCGB1D5P survival associations across molecular data types. SCGB1D5P RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCGB1D5P RNA expression–survival associations across cancer types. High SCGB1D5P expression shows unfavorable associations in LIHC, KIRC and BLCA, but favorable associations in PAAD, GBM and MESO. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SCGB1D5P RNA expression.
This table summarizes SCGB1D5P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SCGB1D5P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCGB1D5P shows higher tumor expression in KIRC. The KIRC box plot shows higher SCGB1D5P RNA expression in tumor versus normal tissue (log2 FC = +0.014, t-test p = .042).
This table shows molecular features associated with SCGB1D5P in patient tissues and cancer cell lines. In patient samples, SCGB1D5P shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
